Literature DB >> 6865945

Neoplastic conversion of preneoplastic Syrian hamster cells: rate estimation by fluctuation analysis.

B D Crawford, J C Barrett, P O Ts'o.   

Abstract

Analysis of the role of gene mutations in the multistep process of neoplastic transformation requires that the discrete steps in carcinogenesis first be dissected. Toward this end, we have isolated and characterized preneoplastic Syrian hamster cells which exhibit in vitro a trait highly correlated with neoplastic conversion in vivo. Previous findings (J. C. Barrett, Cancer Res. 40:91-94, 1980) indicate that spontaneous neoplastic transformation of Syrian hamster cells occurs in at least two steps. An intermediate stage, characterized by an aneuploid established cell line which has a propensity to become neoplastic spontaneously upon further growth in vitro, has been described. These preneoplastic cells differ from diploid early-passage Syrian hamster cells in becoming capable of anchorage-independent growth in semisolid agar, as well as becoming neoplastic in vivo when attached to a solid substrate. Evidence presented here demonstrates that anchorage-independent conversion in vitro is a reliable marker for neoplastic conversion in this cell system. Fluctuation analyses, patterned after those described by Luria and Delbruck for microbial genetics, demonstrate that anchorage-independent variants are generated randomly from clonally derived preneoplastic cells at the rate of 10(-8) to 10(-7) variants per cell per generation. These results establish a multistep stochastic process for transformation in vitro and indicate that conversion to anchorage independence may be necessary for Syrian hamster cells to become tumorigenic. The possible role of gene mutation in this step during neoplastic progression is discussed.

Entities:  

Mesh:

Year:  1983        PMID: 6865945      PMCID: PMC368616          DOI: 10.1128/mcb.3.5.931-945.1983

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  46 in total

1.  Mutagenesis in cultured mammalian cells.

Authors:  N I Shapiro; N B Varshaver
Journal:  Methods Cell Biol       Date:  1975       Impact factor: 1.441

2.  Etiological factors, stages, and the role of the foreign body in foreign body tumorigenesis: a review.

Authors:  K G Brand; L C Buoen; K H Johnson; I Brand
Journal:  Cancer Res       Date:  1975-02       Impact factor: 12.701

3.  In vitro correlates of transformation in C3H/10T1/2 clone 8 mouse cells.

Authors:  P A Jones; W E Laug; A Gardner; C A Nye; L M Fink; W F Benedict
Journal:  Cancer Res       Date:  1976-08       Impact factor: 12.701

4.  Morphological transformation, DNA damage, and chromosomal aberrations induced by a direct DNA perturbation of synchronized Syrian hamster embryo cells.

Authors:  T Tsutsui; J C Barrett; P O Ts'o
Journal:  Cancer Res       Date:  1979-07       Impact factor: 12.701

5.  Somatic mutation as the basis for malignant transformation of BHK cells by chemical carcinogens.

Authors:  N Bouck; G di Mayorca
Journal:  Nature       Date:  1976 Dec 23-30       Impact factor: 49.962

6.  Comparison between mutagenesis in normal and transformed Syrian hamster fibroblasts: difference in the temporal order of HPRT gene replication.

Authors:  T Tsutsui; B D Crawford; P O Ts'o; J C Barrett
Journal:  Mutat Res       Date:  1981-02       Impact factor: 2.433

7.  Malignant hemangioendotheliomas produced by subcutaneous inoculation of Balb/3T3 cells attached to glass beads.

Authors:  C W Boone
Journal:  Science       Date:  1975-04-04       Impact factor: 47.728

8.  Isolation of heat- and cold-sensitive mutants of chinese hamster lung cells affected in their ability to express the transformed state.

Authors:  K Miyashita; T Kakunaga
Journal:  Cell       Date:  1975-06       Impact factor: 41.582

Review 9.  The pathogenesis of cancer metastasis.

Authors:  G Poste; I J Fidler
Journal:  Nature       Date:  1980-01-10       Impact factor: 49.962

10.  Quantitation of fibrinolytic activity of Syrian hamster fibroblasts using 3H-labeled fibrinogen prepared by reductive alkylation.

Authors:  J C Barrett; B D Crawford; P O Ts'o
Journal:  Cancer Res       Date:  1977-04       Impact factor: 12.701

View more
  8 in total

1.  Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbrück fluctuation analysis.

Authors:  T D Tlsty; B H Margolin; K Lum
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

2.  Inducible gene expression by DNA rearrangements in human cells.

Authors:  J P Murnane
Journal:  Mol Cell Biol       Date:  1986-02       Impact factor: 4.272

3.  Comparative properties of untreated and N-nitrosobenzylmethyl-amine-transformed rat esophageal epithelial cell lines.

Authors:  G D Stoner; M S Babcock; M M McCorquodale; W T Gunning; R Jamasbi; N Budd; B Hukku
Journal:  In Vitro Cell Dev Biol       Date:  1989-10

Review 4.  Quantitative genetic analysis of tumor progression.

Authors:  V Ling; A F Chambers; J F Harris; R P Hill
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

5.  Early passage primate cell immortality is independent of tumorigenicity.

Authors:  J C Petricciani; I S Levenbook; D E Wierenga; Y H Qi
Journal:  In Vitro Cell Dev Biol       Date:  1987-07

6.  P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin.

Authors:  D Nielsen; J Eriksen; C Maare; A H Jakobsen; T Skovsgaard
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

7.  MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells.

Authors:  G K Chen; G E Durán; A Mangili; L Beketic-Oreskovic; B I Sikic
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

8.  The second oncogene mil of avian retrovirus MH2 is related to the src gene family.

Authors:  F Galibert; S Dupont de Dinechin; M Righi; D Stehelin
Journal:  EMBO J       Date:  1984-06       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.